Last checked at 30 Oct 2020 12:23
30 October 2020
SkinBioTherapeutics plc
Results of General Meeting & Open Offer
Total Voting Rights
Director/PDMR Dealings
SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders.
Furthermore, the Open Offer closed for acceptances at 11.00 a.m. on 28 October 2020 with final valid applications from Qualifying Shareholders in respect of 2,806,428 Open Offer Shares.
Accordingly, the Company will raise a total of approximately £4.45 million (before expenses) through the Placing and Open Offer and has thus issued and allotted 27,806,428 new Ordinary Shares (conditional on Admission). An application has been made for the 27,806,428 new Ordinary Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 2 November 2020.
The Company expects to apply the net proceeds of the Fundraising to fund the expansion of its technology pipeline in areas such as haircare, oral and acne, consider commercial opportunities for own label product lines and support the transition of the Company from a virtual operation to one with an in-house scientific capability and related infrastructure.
Following Admission, the Company's issued share capital will comprise 155,889,922 Ordinary Shares, of which none are held in treasury. The above figure of 155,889,922 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 14 October 2020.
Details of the proxy votes received on each resolution by SkinBioTherapeutics' Registrar are set out below:
Resolution | For &Discretionary | Against | Withheld | Total votes cast | ||||
|
| Number of votes | % | Number of votes | % | Number of votes | % |
|
1 | Ordinary resolution to authorise the directors to allot shares | 49,705,965 | 100.0% | 10,000 | 0.0% | 4,065 | 0.0% | 49,720,030 |
2 | Ordinary resolution to authorise the directors to allot shares | 49,700,965 | 100.0% | 15,000 | 0.0% | 4,065 | 0.0% | 49,720,030 |
3 | Special resolution to authorise the directors to disapply pre-emption rights | 49,688,465 | 99.9% | 10,000 | 0.0% | 21,565 | 0.0% | 49,720,030 |
4 | Special resolution to authorise the directors to disapply pre-emption rights | 49,688,465 | 99.9% | 15,000 | 0.0% | 16,565 | 0.0% | 49,720,030 |
Directors and other persons discharging managerial responsibility ("PDMRs") have subscribed for shares through the Placing and Open Offer as detailed below.
Director/PDMR | Shares Acquired | Total Holding* | Percentage of Enlarged Share Capital* |
Stuart Ashman | 125,000 | 125,000 | 0.1% |
Catherine Prescott | 62,500 | 118,612 | 0.1% |
Stephen France | 4,607 | 193,495 | 0.1% |
* following Admission of the shares on AIM.
For administrative purposes unconnected with the Placing and Open Offer, certain Directors and other PDMRs have transferred the title of their shares in the Company from their existing nominee into certificated form or a different nominee arrangement as detailed below. The transfers have not resulted in a change in their beneficial interest or in the price of the shares.
Director/PDMR | Shares Transferred |
Martin Hunt | 466,667 |
Douglas Quinn | 444,444 |
Stephen France | 188,888 |
-Ends-
For more information please contact:
SkinBioTherapeutics plc | Tel: +44 (0) 161 468 2760 |
Stuart Ashman, CEO Doug Quinn, CFO |
|
Cenkos Securities plc (Nominated Adviser & Broker) | Tel: +44 (0) 20 7397 8900 |
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales) |
|
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis | SkinBio@instinctif.com
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit:www.skinbiotherapeutics.com.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Stuart John Ashman | |||||
2 | Reason for notification | Acquisition of shares | |||||
a. | Position/Status | CEO | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics Plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Share purchase | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
16p | 125,000 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 2nd November 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Dr Cathy Prescott | |||||
2 | Reason for notification | Acquisition of shares | |||||
a. | Position/Status | Non-Executive Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics Plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Share purchase | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
16p | 62,500 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 2nd November 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Stephen France | |||||
2 | Reason for notification | Acquisition of shares | |||||
a. | Position/Status | PDMR | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Share purchase | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
16p |
4,607 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 2nd November 2020 | |||||
f. | Place of the transaction | London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Martin Hunt | |||||
2 | Reason for notification | Change in title of ownership of holding | |||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Transfer of holding | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
nil |
466,667 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 22/10/2020 | |||||
f. | Place of the transaction |
| |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Stephen France | |||||
2 | Reason for notification | Change in title of ownership of holding | |||||
a. | Position/Status | PDMR | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Transfer of holding | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
nil |
188,888 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | 22/10/2020 | |||||
f. | Place of the transaction |
| |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Doug Quinn | |||||
2 | Reason for notification | Change in title of ownership of holding | |||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Transfer of holding | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
nil |
444,444 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
n/a
| |||||
e. | Date of the transaction | TBC | |||||
f. | Place of the transaction |
| |||||